Abstract
Postoperative delirium (POD) remains a significant challenge in geriatric surgery, often leading to long-term cognitive decline and increased mortality. This study protocol outlines a single-center, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy of S-ketamine in preventing POD among elderly patients undergoing total hip or knee arthroplasty. By utilizing intraspinal anesthesia and a sustained subanesthetic infusion, the researchers aim to overcome the limitations of previous trials and isolate the neuroprotective effects of S-ketamine.
The Pathophysiology of Postoperative Delirium
Postoperative delirium is an acute neuropsychiatric syndrome characterized by fluctuating levels of consciousness and cognitive impairment, affecting up to 24% of elderly surgical patients. The biological basis of POD is thought to involve a cascade of neuroinflammation triggered by surgical trauma.
As illustrated in the figure above, surgery triggers the release of damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs). These activate tissue macrophages, leading to the release of pro-inflammatory cytokines like TNF-α, IL-6, and IL-1β. These cytokines can cross a damaged blood-brain barrier, priming microglia and astrocytes, which ultimately leads to neuronal apoptosis and impaired synaptic plasticity. S-ketamine, an NMDA receptor antagonist, is hypothesized to mitigate this inflammatory response and promote neuroplasticity.
Study Design and Methodology
The proposed trial is a pragmatic RCT involving 372 patients aged 60 and older. The "pragmatic" nature of the study means it includes patients with pre-existing conditions like dementia or depression, making the findings more generalizable to real-world clinical populations.
Participants will be randomized 1:1 into an intervention group receiving S-ketamine or a control group receiving normal saline. A critical component of this protocol is the use of intraspinal anesthesia. Previous studies often utilized general anesthetics (such as propofol or benzodiazepines) that act on GABA receptors, which may have counteracted ketamine's neuroprotective pathways. By using regional anesthesia, this study eliminates those confounding variables.
The intervention consists of:
- Loading Dose: 0.20 mg/kg/h S-ketamine infusion for 1 hour during surgery.
- Maintenance Dose: 0.01 mg/kg/h infusion via a patient-controlled analgesia (PCIA) pump for 48 hours postoperatively.
The primary outcome is the incidence of POD within the first three postoperative days, assessed using the 3D-CAM (3-Minute Diagnostic Interview for CAM-defined Delirium).
Key Insights: Overcoming Previous Failures
The researchers hypothesize that the inconsistent results of previous ketamine trials were due to two main factors: drug-drug interactions and suboptimal dosing.
- The GABA-Ketamine Conflict: By avoiding GABA-ergic drugs common in general anesthesia, the study provides a "clean" environment to observe S-ketamine's true impact on the NMDA-mediated neuroplasticity cascade.
- Extended Protection Window: Rather than a single bolus, the 48-hour infusion covers the peak period of delirium vulnerability, maintaining therapeutic levels of S-ketamine during the critical recovery phase.
Expectations and Future Directions
While the study is currently in the recruitment phase, it is powered to detect a 10% absolute risk reduction in POD incidence. If successful, this trial could establish S-ketamine as a standard pharmacological intervention for protecting the aging brain during major orthopedic surgery. Future work will be needed to determine if these results translate to other surgical types, such as cardiac or abdominal procedures, where inflammatory profiles may differ.
Summary updated